echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > EvaluatePharma: Predict the world's top 20 orphan drugs in 2020

    EvaluatePharma: Predict the world's top 20 orphan drugs in 2020

    • Last Update: 2014-12-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: arterial network 2014-12-19 the concept of orphan drug originally came from the pharmaceutical industry in Europe and the United States, which was translated into Chinese as orphan drug Orphan drugs are used to prevent, treat and diagnose rare diseases Due to the small number of patients with rare diseases, low market demand and high cost of research and development, few pharmaceutical companies pay attention to the research and development of their treatment drugs, so this literal translation is quite appropriate Rare diseases are those with very low incidence rate According to the definition of the World Health Organization (who), the rare disease is the disease that the number of patients accounts for 0.65 ‰ - 1 ‰ of the total population According to the specific situation of each country in the world, there are some differences in the recognition standards of rare diseases For example, the United States defines rare diseases as diseases with fewer than 200 thousand people (or less than 1/1500) of the disease each year Japan has stipulated that rare diseases are diseases with a disease less than 50 thousand (or less than 1/2500 of the incidence), while the incidence rate of less than 1/10000 in Taiwan is the standard of rare diseases In China, rare diseases are defined as diseases with a prevalence of less than 1 / 500000 The rare disease of "progressive frostbite" is widely known this summer with the viral spread of ice bucket challenge on social networks, and more and more rare diseases are gradually known by people According to statistics, there are 6000-8000 rare diseases in the world, accounting for about 10% of the known diseases According to the data recently released by evaluate Pharma, the world's leading medical and health industry and market research company, it is estimated that by 2020, the global market value of orphan drugs will reach 176 billion US dollars, close to 19% of the total sales of prescription drugs The following is the analysis and forecast of orphan drug sales and market share of prescription drugs in the world from 2000 to 2020 by evaluate Pharma: the analysis and forecast of orphan drug sales and market share of prescription drugs in the world (2000-2020) Bristol Myers Squibb's rising annual sales of 11.1 billion US dollars exceeds Novartis' evaluation Pharma's 20-2020 Big orphan drug companies predict that Bristol Myers Squibb will surpass Novartis as the largest orphan drug company by 2020, benefiting from the rapid growth of cancer immunotherapy drug opdivo At that time, BMS's orphan drug sales will reach US $11.1 billion, of which US $6 billion will come from opdivo Evaluatepharma predicts that in 2020, the world's top 20 orphan drug enterprises 1 Bristol Myers Squibb's orphan drug sales in 2013: US $2.3 billion It is estimated that in 2020, the orphan drug sales will be US $11.1 billion Novartis's orphan drug sales in 2013: US $11.3 billion It is estimated that in 2020, the orphan drug sales will be US $10.5 billion Celgene( New base medicine) sales of orphan drugs in 2013: 5.7 billion US dollars; sales of orphan drugs in 2020: 10.4 billion US dollars; Roche sales of orphan drugs in 2013: 9.5 billion US dollars; sales of orphan drugs in 2020: 9.9 billion US dollars; Pfizer sales of orphan drugs in 2013: 5.3 billion US dollars; sales of orphan drugs in 2020: 9.4 billion US dollars; 6 Alexion pharmaceuticals 2013 orphan drug sales: US $1.6 billion estimated 2020 orphan drug sales: US $6.3 billion Sanofi 2013 orphan drug sales: US $3.3 billion estimated 2020 orphan drug sales: US $5.7 billion 8 vertex pharmaceuticals 2013 orphan drug sales: US $400 million Estimated sales of orphan drugs in 2020: 5.5 billion US dollars 9 GlaxoSmithKline's sales of orphan drugs in 2013: 1.9 billion US dollars estimated sales of orphan drugs in 2020: 5.1 billion US dollars 10 Merck & Co's sales of orphan drugs in 2013: 1.3 billion US dollars estimated sales of orphan drugs in 2020: 4.5 billion US dollars 11 Johnson & Johnson's 2013 Sales of orphan drugs in 2020: 2.1 billion US dollars; sales of orphan drugs in 2020: 4.2 billion US dollars; sales of Baxter International (Baxter) in 2013: 3.3 billion US dollars; sales of orphan drugs in 2020: 4 billion US dollars; sales of Novo Nordisk in 2013: 2.7 billion US dollars; sales of orphan drugs in 2020: 39 14 Bayer's sales of orphan drugs in 2013: 4.2 billion US dollars Estimated sales of orphan drugs in 2020: 3.8 billion US dollars 15 Eli Lilly's sales of orphan drugs in 2013: 3 billion US dollars Estimated sales of orphan drugs in 2020: 3.7 billion US dollars 16 Pharmaceuticals' sales of orphan drugs in 2013: estimated 2020 Sales of orphan drugs in 2013: US $3.6 billion 17 Shire sales of orphan drugs in 2013: US $1.8 billion estimated sales of orphan drugs in 2020: US $3.5 billion 18 Actelion sales of orphan drugs in 2013: US $1.9 billion estimated sales of orphan drugs in 2020: US $3.3 billion 19 Amgen sales of orphan drugs in 2013: US $1.6 billion It is estimated that in 2020, the sales volume of orphan drugs will reach 3.3 billion US dollars In 2013, the sales volume of orphan drugs will reach 3 billion US dollars In 2020, the sales volume of orphan drugs will reach 2.8 billion US dollars In 2020, the sales volume of lenalidomide will exceed 8 billion US dollars In 2020, evaluatepharma, the king of the sales volume of orphan drugs, predicts that the Revlimid of celgene will be 2020 The world's largest orphan drug sales in, sales can exceed $8 billion The drug was approved for marketing in November 2005, and is the first drug for myelodysplastic syndrome in the world In addition, it has been approved for the treatment of rare non Hodgkin's lymphoma and multiple myeloma, and several indications are under development Evaluatepharma also predicted the top 20 products in the sales volume of rare drugs in 2020 The results are summarized as follows: evaluatepharma predicted that 20 orphan drugs with the highest sales volume in the world in 2020 1 The sales volume of Revlimid / celgene in 2013: 4.28 billion US dollars The sales volume of Revlimid in 2020: 8.012 billion US dollars Revlimid is mainly used for the treatment of transfusion dependent anemia patients with myelodysplastic syndrome with 5q deletion cytogenetic abnormality 2 2013 sales volume of opdivo / Bristol Myers Squibb: - estimated sales volume in 2020: $6.033 billion In July 2014, nivolumab has been approved for marketing in Japan for the treatment of melanoma The drug will be marketed in Japan under the commercial name of opdivo Nivolumab is the only cutting-edge drug approved in Japan recently 3 Sales volume of rituxan / Roche in 2013: US $7.503 billion Sales volume of rituxan in 2020: US $5.689 billion Rituxan is suitable for the treatment of recurrent or resistant central follicular lymphoma (B-cell non Hodgkin's lymphoma of subtypes B, C and D of the international working classification) 4 Sales of soliris / pharmaceuticals in 2013: US $1.551 billion estimated sales in 2020: US $5.510 billion soliris is the first orphan drug for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), which has about 8000 patients in the United States 5 Sales volume of vx-809 + ivacftor / vertex pharmaceuticals in 2013: - estimated sales volume in 2020: $4227 million On July 27, 2014, the European Commission has approved kalydeco (ivacftor) for cystic fibrosis (CF) patients with at least one copy of G551D mutation in the gene of cystic fibrosis transmembrane conductance regulator (CFTR) in the age group of 6 and above Kalydeco is the first drug to target the underlying cause of the disease Cystic fibrosis is a rare genetic disease caused by CFTR protein deficiency or deletion 6 Sales volume of keytruda / Merck & Co in 2013: – estimated sales volume in 2020: US $3.879 billion Merck announced on September 4, 2014 that its keytruda (pembrolizumab) officially became the first PD-1 monoclonal antibody approved by the US Food and Drug Administration (FDA) The indication of the drug is unresectable or metastatic melanoma 7 The sales volume of imbruvica / pharmaceuticals in 2013 is US $14 million, and the sales volume in 2020 is US $3.602 billion On November 13, 2013, the US Food and Drug Administration (FDA) approved imbruvica (ibrutinib) for the treatment of mantle cell lymphoma (MCL) MCL is a rare non-Hodgkin's lymphoma, accounting for about 6% of all non-Hodgkin's lymphoma cases in the United States Usually when MCL is diagnosed, cancer cells have spread to lymph nodes, bone marrow and other organs 8 Gazyva / Roche 2013 sales: US $03 million estimated 2020 sales: US $2.528 billion FDA approved the combination of gazyva (obinutuzumab) and nitrogen mustard benzoate for the treatment of untreated chronic lymphocytic leukemia (CLL) CLL is a blood and bone marrow disease that usually deteriorates 9 Sales volume of obeticolic acid / intercept pharmaceuticals in 2013: – estimated sales volume in 2020: $2.522 billion obeticolic acid is a new drug, which is used to study patients who do not fully respond or can not tolerate the old standard treatment drug ursodeoxycholic acid Obeticolic acid is also being tested to treat a more common form of fatty liver, nonalcoholic steatohepatitis 10 Elelyso / Pfizer's sales in 2013: $49 million estimated sales in 2020: $2.480 billion on May 1, 2012, FDA announced the approval of long-term enzyme replacement therapy elelyso (taliglucerase alfa) for the treatment of rare genetic diseases - Gaucher's disease Patients with Gaucher's disease cannot produce enough glucocerebrosidase The deficiency of this enzyme leads to the accumulation of fatty substances in spleen, liver, kidney and other organs The main signs of Gaucher's disease are liver or spleen damage, anemia, thrombocytopenia and bone problems 11 Tasigna / Novartis sales in 2013: 1.266 billion US dollars estimated sales in 2020: 2.468 billion US dollars Tasigna is mainly used for the treatment of adult patients newly diagnosed with Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML) At the same time, it is also used for the treatment of imatinib resistant or intolerable chronic phase (CP) and accelerated phase (AP) Ph + CML in adult patients 12 Yevoy / Bristol Myers Squibb 2013 sales: US $960 million estimated 2020 sales: US $2377 million FDA approved the listing of yivoy (ipilimumab) developed by Bristol Myers Squibb pharmaceutical company on March 26, 2011 for the treatment of advanced melanoma 13 Pomalyst / celgene 2013 sales: US $305 million estimated sales in 2020: US $2.097 billion pomalidomide is a new immunomodulator developed by celgene Pharmaceutical Co., Ltd under the trade name of pomalyst On February 8, 2013, FDA approved the drug for the treatment of recurrent and refractory multiple myeloma 14 Alimta / Eli Lilly 2013 sales: US $305 million estimated 2020 sales: US $2.097 billion Alimta It is a multi-target anti metabolism anti-tumor drug It is a folic acid antagonist It can inhibit thymidylate synthetase, dihydrofolate reductase, glycine ribonucleoside formyltransferase and other folate dependent enzymes These enzymes participate in the biosynthesis of thymine nucleoside and purine nucleoside, so as to achieve the anti-tumor effect 15 Sales volume of dcvax-l / biotherapeutics in 2013: – estimated sales volume in 2020: $2.046 billion according to Reuters 201
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.